6. Ilumya

India's Sun Pharma
(Sun Pharma)

Active ingredient: tildrakizumab-asmn 
Disease: psoriasis 
Peak sales estimate: n/a
Approved: Mar. 21 
Company: Sun Pharma 

The scoop: For Sun, the approval of Ilumya was a milestone in its pivot toward specialty pharma after several years as an established generics player. But unfortunately for the Indian pharma, the green light didn’t come fast enough to beat out rival Tremfya from well-established psoriasis player Johnson & Johnson. While Ilumya, picked up from Merck in an $80 million licensing deal, might not have locked up the first-to-market advantage, though, it does have a dosing advantage over Tremfya. It requires doses just every 12 weeks after two initial treatments, compared with Tremfya’s every-8-weeks schedule. — Carly Helfand

6. Ilumya

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.